الصفحة الرئيسية>>Signaling Pathways>> Chromatin/Epigenetics>> HIF>>AKB-6899

AKB-6899

رقم الكتالوجGC62277

Ro24-7429 هو مناهض لبروتين Tat فعال وفعال عن طريق الفمRo24-7429 هو أيضًا مثبط عامل النسخ 1 المرتبط بالتشغيل (RUNX1)Ro24-7429 له تأثيرات مضادة لفيروس نقص المناعة البشرية ومضادة للالتهاب ومضادة للالتهابات

Products are for research use only. Not for human use. We do not sell to patients.

AKB-6899 التركيب الكيميائي

Cas No.: 1007377-55-0

الحجم السعر المخزون الكميّة
5 mg
198٫00
متوفر
10 mg
315٫00
متوفر
25 mg
666٫00
متوفر
50 mg
1080٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com

مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AKB-6899, a prolyl hydroxylase domain 3 (PHD3) inhibitor, is a selective HIF-2α stabilizer. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, and has antitumor and antiangiogenic effects[1].

AKB-6899 (10 μM; 24 hours) increases the leves of HIF-2α protein, with no corresponding increase in HIF-1α. AKB-6899 also increases soluble form of the VEGF receptor (sVEGFR-1) production from GM-CSF-treated macrophages, with no effect on HIF-1α accumulation or VEGF production[1].

AKB-6899 (17.5 mg/kg; i.p.; 3 times per week; for 16 days) treatment significantly reduces tumor growth in a murine melanoma model[1].

[1]. Julie M Roda, et al. Stabilization of HIF-2α induces sVEGFR-1 production from tumor-associated macrophages and decreases tumor growth in a murine melanoma model. J Immunol. 2012 Sep 15;189(6):3168-77.

مراجعات

Review for AKB-6899

Average Rating: 5 ★★★★★ (Based on Reviews and 23 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AKB-6899

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.